Screener
Travere Therapeutics, Inc. TVTX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Assets | March 31, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $78,362 | $93,035 |
| Marketable debt securities, at fair value | 186,314 | 229,761 |
| Accounts receivable, net | 87,302 | 80,134 |
| Inventory | 6,356 | 5,875 |
| Prepaid expenses and other current assets | 34,347 | 28,760 |
| Total current assets | 392,681 | 437,565 |
| Long-term inventory | 30,698 | 30,280 |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s cash & equivalents?
- Travere Therapeutics, Inc. (TVTX) reported cash & equivalents of $78.36M in Q1 2026.
- How has Travere Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Travere Therapeutics, Inc.'s cash & equivalents increased by 26.6% year-over-year, from $61.9M to $78.36M.
- What is the long-term trend for Travere Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s cash & equivalents has grown at a 1.9% compound annual growth rate (CAGR), from $84.77M to $93.04M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Travere Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude